Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer
Sponsor: First Affiliated Hospital of Fujian Medical University
Summary
As a new dual targeting PET radiotracer, 68Ga-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-Biotin in patients with various types of cancer and compared them with the results of 68Ga-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAPI.
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-03-01
Completion Date
2026-12-31
Last Updated
2024-12-18
Healthy Volunteers
No
Conditions
Interventions
68Ga-FAPI-Biotin
Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI-Biotin. Tracer doses of 68Ga-FAPI-Biotin will be used to detect tumors by PET/CT
68Ga-FAPI/18F-FDG
Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
Locations (1)
First Affiliated Hospital of Fujian Medical University
Fuzhou, China